MX2019005076A - Compuestos y métodos para modular la cinasa de linfocitos t inducible por interleucina 2. - Google Patents

Compuestos y métodos para modular la cinasa de linfocitos t inducible por interleucina 2.

Info

Publication number
MX2019005076A
MX2019005076A MX2019005076A MX2019005076A MX2019005076A MX 2019005076 A MX2019005076 A MX 2019005076A MX 2019005076 A MX2019005076 A MX 2019005076A MX 2019005076 A MX2019005076 A MX 2019005076A MX 2019005076 A MX2019005076 A MX 2019005076A
Authority
MX
Mexico
Prior art keywords
inducible
compounds
methods
cell kinase
modulating interleukin
Prior art date
Application number
MX2019005076A
Other languages
English (en)
Inventor
Hudson Ryan
- Marie Beausoleil Anne
Original Assignee
Corvus Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Corvus Pharmaceuticals Inc filed Critical Corvus Pharmaceuticals Inc
Publication of MX2019005076A publication Critical patent/MX2019005076A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/54—Nitrogen and either oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/5545—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having eight-membered rings not containing additional condensed or non-condensed nitrogen-containing 3-7 membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Abstract

Se proporcionan en la presente, entre otros, métodos y compuestos para modular la cinasa de linfocitos T inducible por interleucina 2.
MX2019005076A 2016-11-03 2017-11-03 Compuestos y métodos para modular la cinasa de linfocitos t inducible por interleucina 2. MX2019005076A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662417083P 2016-11-03 2016-11-03
PCT/US2017/059871 WO2018089261A2 (en) 2016-11-03 2017-11-03 Compounds and methods for modulating interleukin-2-inducible t-cell kinase

Publications (1)

Publication Number Publication Date
MX2019005076A true MX2019005076A (es) 2019-11-12

Family

ID=62109599

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019005076A MX2019005076A (es) 2016-11-03 2017-11-03 Compuestos y métodos para modular la cinasa de linfocitos t inducible por interleucina 2.

Country Status (14)

Country Link
US (2) US11008314B2 (es)
EP (1) EP3534899B1 (es)
JP (2) JP7236996B2 (es)
KR (1) KR102540515B1 (es)
CN (1) CN110099684B (es)
AU (1) AU2017358901B2 (es)
CA (1) CA3042252A1 (es)
DK (1) DK3534899T3 (es)
ES (1) ES2926153T3 (es)
IL (1) IL266181B2 (es)
MX (1) MX2019005076A (es)
PT (1) PT3534899T (es)
WO (1) WO2018089261A2 (es)
ZA (1) ZA201903071B (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9227978B2 (en) 2013-03-15 2016-01-05 Araxes Pharma Llc Covalent inhibitors of Kras G12C
JO3805B1 (ar) 2013-10-10 2021-01-31 Araxes Pharma Llc مثبطات كراس جي12سي
US10246424B2 (en) 2015-04-10 2019-04-02 Araxes Pharma Llc Substituted quinazoline compounds and methods of use thereof
EP3356347A1 (en) 2015-09-28 2018-08-08 Araxes Pharma LLC Inhibitors of kras g12c mutant proteins
EP3356359B1 (en) 2015-09-28 2021-10-20 Araxes Pharma LLC Inhibitors of kras g12c mutant proteins
US10975071B2 (en) 2015-09-28 2021-04-13 Araxes Pharma Llc Inhibitors of KRAS G12C mutant proteins
US10858343B2 (en) 2015-09-28 2020-12-08 Araxes Pharma Llc Inhibitors of KRAS G12C mutant proteins
AU2016355433C1 (en) 2015-11-16 2021-12-16 Araxes Pharma Llc 2-substituted quinazoline compounds comprising a substituted heterocyclic group and methods of use thereof
IL266181B2 (en) * 2016-11-03 2024-04-01 Corvus Pharmaceuticals Inc Compounds and methods for up-regulating the inducible kinase of interleukin-2 in T-cells
WO2018140513A1 (en) 2017-01-26 2018-08-02 Araxes Pharma Llc 1-(3-(6-(3-hydroxynaphthalen-1-yl)benzofuran-2-yl)azetidin-1yl)prop-2-en-1-one derivatives and similar compounds as kras g12c modulators for treating cancer
WO2018140512A1 (en) 2017-01-26 2018-08-02 Araxes Pharma Llc Fused bicyclic benzoheteroaromatic compounds and methods of use thereof
US11358959B2 (en) 2017-01-26 2022-06-14 Araxes Pharma Llc Benzothiophene and benzothiazole compounds and methods of use thereof
US11059819B2 (en) 2017-01-26 2021-07-13 Janssen Biotech, Inc. Fused hetero-hetero bicyclic compounds and methods of use thereof
US11136308B2 (en) 2017-01-26 2021-10-05 Araxes Pharma Llc Substituted quinazoline and quinazolinone compounds and methods of use thereof
WO2018218069A1 (en) 2017-05-25 2018-11-29 Araxes Pharma Llc Quinazoline derivatives as modulators of mutant kras, hras or nras
KR20200010306A (ko) 2017-05-25 2020-01-30 아락세스 파마 엘엘씨 Kras의 공유적 억제제
BR112021007726A2 (pt) * 2018-10-24 2021-07-27 Araxes Pharma Llc derivados de 2-(2-acriloil-2,6-diazaspiro[3.4] octan-6-il)-6-(1h-indazol-4-il)-benzonitrilo e compostos relacionados como inibidores de proteína kras mutante g12c para inibir metástase tumoral
WO2021262636A2 (en) * 2020-06-23 2021-12-30 Dana-Farber Cancer Institute, Inc. Compounds for targeted degradation of interleukin-2-inducible t-cell kinase and methods of use
CN114621213B (zh) * 2022-03-23 2023-12-08 合肥美诺医药有限公司 含噻唑类化合物及其中间体与应用
CN114605404B (zh) * 2022-03-23 2024-01-05 合肥美诺医药有限公司 一种新型含噻唑类化合物、中间体及其应用
WO2023196278A1 (en) * 2022-04-05 2023-10-12 Corvus Pharmaceuticals, Inc. Itk inhibitors for increasing th1 cell activity

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2257461T3 (es) 2000-12-21 2006-08-01 Bristol-Myers Squibb Company Inhibidores de tiazolilo de tirosina quinasas de la familia tec.
CA2458375A1 (en) * 2001-08-24 2003-03-06 Pharmacia & Upjohn Company Substituted-heteroaryl-7-aza¬2.2.1|bicycloheptanes for the treatment of disease
RU2006111093A (ru) * 2003-09-06 2007-10-27 Вертекс Фармасьютикалз Инкорпорейтед (Us) Модуляторы атр-связывающих кассетных транспортеров
JP2010529203A (ja) 2007-06-11 2010-08-26 ブリストル−マイヤーズ スクイブ カンパニー １，３−ジヒドロキシ置換フェニルアミドグルコキナーゼ活性化剤
US20100113520A1 (en) * 2008-11-05 2010-05-06 Principia Biopharma, Inc. Kinase knockdown via electrophilically enhanced inhibitors
US20110207736A1 (en) * 2009-12-23 2011-08-25 Gatekeeper Pharmaceuticals, Inc. Compounds that modulate egfr activity and methods for treating or preventing conditions therewith
US9649313B2 (en) 2012-11-26 2017-05-16 The University Of North Carolina At Chapel Hill Use of ITK inhibitors for the treatment of cancer
CN105164112B (zh) 2013-01-31 2017-10-13 中国科学院上海药物研究所 酰胺类化合物及其制备方法、药物组合物和用途
WO2016065138A1 (en) 2014-10-22 2016-04-28 Dana-Farber Cancer Institute, Inc. Thiazolyl-containing compounds for treating proliferative diseases
US10988394B2 (en) * 2014-11-19 2021-04-27 Hach Lange Gmbh Cost control of wastewater treatment based on regulatory period
CN105884711A (zh) 2014-12-16 2016-08-24 中国药科大学 噻唑类化合物、其制备方法及其在制药中的用途
CA2996978A1 (en) 2015-09-09 2017-03-16 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinases
IL266181B2 (en) * 2016-11-03 2024-04-01 Corvus Pharmaceuticals Inc Compounds and methods for up-regulating the inducible kinase of interleukin-2 in T-cells

Also Published As

Publication number Publication date
US20190375743A1 (en) 2019-12-12
JP2023029752A (ja) 2023-03-06
WO2018089261A3 (en) 2018-08-02
ZA201903071B (en) 2021-09-29
US11008314B2 (en) 2021-05-18
AU2017358901B2 (en) 2023-01-05
US11897874B2 (en) 2024-02-13
KR20190089891A (ko) 2019-07-31
IL266181B2 (en) 2024-04-01
EP3534899A4 (en) 2020-04-29
CN110099684B (zh) 2022-11-11
EP3534899B1 (en) 2022-06-01
KR102540515B1 (ko) 2023-06-05
AU2017358901A1 (en) 2019-05-30
EP3534899A2 (en) 2019-09-11
IL266181B1 (en) 2023-12-01
US20220363676A1 (en) 2022-11-17
CN110099684A (zh) 2019-08-06
PT3534899T (pt) 2022-07-07
ES2926153T3 (es) 2022-10-24
WO2018089261A2 (en) 2018-05-17
IL266181A (en) 2019-06-30
JP7236996B2 (ja) 2023-03-10
CA3042252A1 (en) 2018-05-17
JP2019536763A (ja) 2019-12-19
DK3534899T3 (da) 2022-06-20

Similar Documents

Publication Publication Date Title
MX2019005076A (es) Compuestos y métodos para modular la cinasa de linfocitos t inducible por interleucina 2.
MX2021006237A (es) Anticuerpos anti-tigit, anticuerpos anti-pvrig y combinaciones de estos.
PH12017501999A1 (en) K-ras modulators
MX2019012532A (es) Moduladores de k-ras.
MX2019007030A (es) Composiciones y metodos para el tratamiento del cancer.
AU2018258581A8 (en) RAF-degrading conjugate compounds
MX2019007021A (es) Anticuerpos il-11ra.
PH12016502142A1 (en) Anti-ptk7 antibody-drug conjugates
AU2019268074A1 (en) Methods for treating hepcidin-mediated disorders
MX2016012058A (es) 2-(2,4-difluorofenil)-1,1-difluoro-1-(5-sustituido-piridin-2-il)- 3-(1h-tetrazol-1-il)propan-2-oles y procedimientos para su preparacion.
MX2018010971A (es) Compuestos y métodos para modular la tirosina cinasa de bruton.
MX2018008407A (es) Dispositivo secundario.
MX2020003712A (es) Union giratoria de pasaje multiple.
MX2020003706A (es) Aminoimidazopiridazinas como inhibidores de cinasa.
MX2023006458A (es) Oligosacaridos inmunomoduladores.
MX2022007955A (es) Regimenes de dosificacion de erdafitinib.
PH12017500071A1 (en) Therapeutic agent for keratoconjunctive disorder
MX2020003611A (es) Metodos de refuerzo del pozo.
MX2019009199A (es) Composiciones y métodos para modular ppp2r1a.
MX2020004664A (es) Dispositivo generador de humo mejorado.
UA99903U (ru) Вяжущее для брикетирования
AU364097S (en) Transportable accommodation pod called Gunya Pod
UA106748U (uk) Пристрій для формування паливних матеріалів
UA99992U (ru) 2-оксо-4-фенил-5-циано-1,2,3,4-тетрагидропиридин-6-тиолат n-метилморфолиния
UA93482U (uk) Четвертинні солі 1-[(2,4-дитретбутил)феноксі-1-етоксі]-3-(n-алкілдіалкіламоній)-2-пропанолу